New drug STAR-0310 takes first step: safety check in healthy volunteers
NCT ID NCT06782477
First seen Nov 05, 2025 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This early-stage trial tests the safety and tolerability of a new drug, STAR-0310, in 40 healthy adults. Participants receive a single dose (either the drug or a placebo) and are monitored for side effects, how the drug moves through the body, and immune reactions. The goal is to gather initial safety data before testing in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Clinical Research Unit - Early Clinical Development
Austin, Texas, 78744, United States
Conditions
Explore the condition pages connected to this study.